What is the address of Labo Phytophar?

The registered office of Labo Phytophar is located at Handelsstraat 19, 8020 Oostkamp.

Is Labo Phytophar still active?

Yes. According to the CBE (29 October 2026) Labo Phytophar is active, legal situation “Normale toestand”, started on 18 May 1999.

Is Labo Phytophar registered on Peppol?

Yes, Labo Phytophar is registered on the Peppol network with ID 0208:0466063323.

What is the enterprise number of Labo Phytophar?

The enterprise number of Labo Phytophar is BE0466063323.

When was Labo Phytophar founded?

Labo Phytophar was founded on 18 May 1999.

Who are the directors of Labo Phytophar?

According to the 2025 annual accounts, the directors of Labo Phytophar are: PVR INVEST BV.

Is Labo Phytophar a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 18 May 1999; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Labo Phytophar make in 2025?

Labo Phytophar posted a profit after taxes of € 169,685 in financial year 2025.

What is the revenue of Labo Phytophar?

As a small company, Labo Phytophar is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 3,292,553.

How much does an employee at Labo Phytophar earn?

The average wage cost per full-time employee at Labo Phytophar was € 73,400 in 2025: staff costs of € 2.5 million for 33.5 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does Labo Phytophar have?

According to the 2025 annual accounts, Labo Phytophar has 33.5 full-time equivalents (FTE).

Does Labo Phytophar have a website?

Yes, Labo Phytophar has a website at phytophar.be.

Labo Phytophar (Public Limited) - Oostkamp - BE0466063323

Q: What does Labo Phytophar do?

Labo Phytophar is registered with the CBE as active in: Vervaardiging van farmaceutische grondstoffen. Public Limited, started on 18 May 1999, 1 establishment.

Dossier Labo Phytophar, printed on 29 October 2026 from databakkes.be/en/0466063323/labo-phytophar. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 37.4 to 33.5.

Financials

Financial year 2025

Labo Phytophar from Oostkamp, company number BE0466063323, closed financial year 2025 with a result of € 169,685 after tax. For that financial year Labo Phytophar recorded a gross margin of € 3.3 million and equity of € 2.1 million. Compared with financial year 2024, the result moved from € -40,782 to € 169,685. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on January 30, 2026.

What it is worth Growing

€ 2.1 million

▲ 8% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 169,685

▲ still € 40,782 loss in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 381,775

▲ 250% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 1.9 million.

People and assets in 2025

Full-time equivalents

33.5

▼ 1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 2.5 million

▲ 5% vs 2024

€ 73,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 710,972

▼ 14% vs 2024

Of which on lease € 696,737.

Debts at end 2025

Bank debt ≈ 5 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 3.5 million

▼ 9% vs 2024

€ 531,834 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.

Owed to suppliers

€ 1.3 million

▼ 21% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 631,561

▲ 29% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 2,521,189 Gross margin 2022: € 2,521,189 First fiscal year in the series	€ 3,361,415 Gross margin 2023: € 3,361,415 ▲ 33% vs 2022 (€ 2,521,189) Favourable step	€ 3,090,782 Gross margin 2024: € 3,090,782 ▼ 8% vs 2023 (€ 3,361,415) Unfavourable step	€ 3,292,553 Gross margin 2025: € 3,292,553 ▲ 7% vs 2024 (€ 3,090,782) Favourable step	▲ 7%
Profit after taxes	€ -168,694 Profit after taxes 2022: € -168,694 First fiscal year in the series	€ 7,540 Profit after taxes 2023: € 7,540 ▲ € 176,234 vs 2022 (€ -168,694) Favourable step	€ -40,782 Profit after taxes 2024: € -40,782 ▼ € 48,323 vs 2023 (€ 7,540) Unfavourable step	€ 169,685 Profit after taxes 2025: € 169,685 ▲ € 210,468 vs 2024 (€ -40,782) Favourable step	▲ € 210,468
Equity	€ 1,994,650 Equity 2022: € 1,994,650 First fiscal year in the series	€ 1,981,461 Equity 2023: € 1,981,461 ▼ 1% vs 2022 (€ 1,994,650) Unfavourable step	€ 1,910,647 Equity 2024: € 1,910,647 ▼ 4% vs 2023 (€ 1,981,461) Unfavourable step	€ 2,059,563 Equity 2025: € 2,059,563 ▲ 8% vs 2024 (€ 1,910,647) Favourable step	▲ 8%
Total debts	€ 9,921,366 Total debts 2022: € 9,921,366 First fiscal year in the series	€ 8,968,252 Total debts 2023: € 8,968,252 ▼ 10% vs 2022 (€ 9,921,366) Favourable step	€ 9,007,264 Total debts 2024: € 9,007,264 Unchanged (€ 8,968,252) Unfavourable step	€ 8,876,024 Total debts 2025: € 8,876,024 ▼ 1% vs 2024 (€ 9,007,264) Favourable step	▼ 1%
Cash	€ 18,365 Cash 2022: € 18,365 First fiscal year in the series	€ 152,211 Cash 2023: € 152,211 ▲ € 133,846 vs 2022 (€ 18,365) Favourable step	€ 109,007 Cash 2024: € 109,007 ▼ 28% vs 2023 (€ 152,211) Unfavourable step	€ 381,775 Cash 2025: € 381,775 ▲ 250% vs 2024 (€ 109,007) Favourable step	▲ 250%
Land & buildings	€ 2,883,588 Land & buildings 2022: € 2,883,588 First fiscal year in the series	€ 2,674,444 Land & buildings 2023: € 2,674,444 ▼ 7% vs 2022 (€ 2,883,588) Unchanged	€ 2,480,123 Land & buildings 2024: € 2,480,123 ▼ 7% vs 2023 (€ 2,674,444) Unchanged	€ 2,292,570 Land & buildings 2025: € 2,292,570 ▼ 8% vs 2024 (€ 2,480,123) Unchanged	▼ 8%
Retained profit	€ 1,744,953 Retained profit 2022: € 1,744,953 First fiscal year in the series	€ 1,752,493 Retained profit 2023: € 1,752,493 Unchanged (€ 1,744,953) Favourable step	€ 1,711,711 Retained profit 2024: € 1,711,711 ▼ 2% vs 2023 (€ 1,752,493) Unfavourable step	€ 1,881,396 Retained profit 2025: € 1,881,396 ▲ 10% vs 2024 (€ 1,711,711) Favourable step	▲ 10%
Bank debt	€ 4,665,187 Bank debt 2022: € 4,665,187 First fiscal year in the series	€ 3,933,546 Bank debt 2023: € 3,933,546 ▼ 16% vs 2022 (€ 4,665,187) Favourable step	€ 3,876,846 Bank debt 2024: € 3,876,846 ▼ 1% vs 2023 (€ 3,933,546) Favourable step	€ 3,517,196 Bank debt 2025: € 3,517,196 ▼ 9% vs 2024 (€ 3,876,846) Favourable step	▼ 9%
Balance sheet total	€ 11,916,017 Balance sheet total 2022: € 11,916,017 First fiscal year in the series	€ 10,949,713 Balance sheet total 2023: € 10,949,713 ▼ 8% vs 2022 (€ 11,916,017) Unchanged	€ 10,917,912 Balance sheet total 2024: € 10,917,912 Unchanged (€ 10,949,713) Unchanged	€ 10,935,587 Balance sheet total 2025: € 10,935,587 Unchanged (€ 10,917,912) Unchanged
Employees (FTE)	34.1 Employees (FTE) 2022: 34.1 First fiscal year in the series	37.4 Employees (FTE) 2023: 37.4 ▲ 3.3 vs 2022 (34.1) Unchanged	34.5 Employees (FTE) 2024: 34.5 ▼ 2.9 vs 2023 (37.4) Unchanged	33.5 Employees (FTE) 2025: 33.5 ▼ 1 vs 2024 (34.5) Unchanged	▼ 1

Key figures of Labo Phytophar, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 January 2027.

What happened to Labo Phytophar?

What happened at Labo Phytophar in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2026 PVR INVEST BV stepped down as director. NBB
Jan 30, 2026 New annual accounts for financial year 2025: profit of € 169,685. Source: NBB ↗
2020 PVR INVEST BV became a director. NBB
Sep 22, 1999 New establishment in Oostkamp. KBO
May 18, 1999 Start of the company according to the CBE. KBO

In short

From € 168,694 loss in 2022 to € 169,685 profit in 2025.

Paid € 8,024 in corporate taxes since 2022.

Best year ever: 2025, with € 169,685 profit.

On average € 98,300 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Labo Phytophar

PHARMA CONSULTING & INDUSTRIES B.V. 100%

LABORATORIOS PHYTOPHAR LDA 99.1%

It owns 100% of PHARMA CONSULTING & INDUSTRIES B.V. and 99.1% of LABORATORIOS PHYTOPHAR LDA itself.

Directors

According to the 2025 annual accounts

PVR INVEST BV

Managing director · represented by Pieter VAN ROMPAY

since 2020 · until 2026

Establishments

Establishment units

Physical locations of this company

Registered office

Handelsstraat 19

8020 Oostkamp

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS phytophar.be

Canonical: https://www.phytophar.be

Technologies

Advanced Custom FieldsGoogle App EngineLodashPHPPWAReactTidioWixlazysizes

Certifications & Partners

ISO 22000

Hosting & Email

Email provider

Microsoft 365

Hosting

WIX_COM, IL

Website info

HTTPS Ja

Languages EN

Features

Webshop Live chat

Security

✓ HTTPS

✓ SPF

✓ DMARC

Details

Company number

0466.063.323

VAT number

BE 0466.063.323

Registered office

Handelsstraat 19, 8020 Oostkamp

Names & denominations

Labo Phytophar

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

18 May 1999

Peppol

Active · Active since 1 Jan 2001

Contact

phytophar.be

Activities · NACE

Vervaardiging van farmaceutische grondstoffen

Vervaardiging van specerijen, sauzen en kruiderijen

Vervaardiging van geneesmiddelen

View on CBE Public ↗ Annual accounts (NBB) ↗

Labo Phytophar

Warning lights

Financials

What happened to Labo Phytophar?

Management

Directors

Establishments

Establishment units

Website

Technologies

Certifications & Partners

Hosting & Email

Website info

Features

Security

Details

Frequently asked questions